Comparative Pharmacology
Head-to-head clinical analysis: CONRAY 30 versus SCANLUX 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY 30 versus SCANLUX 300.
CONRAY 30 vs SCANLUX-300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iothalamate meglumine is a water-soluble iodinated radiographic contrast agent that attenuates X-rays, providing vascular and organ opacification. It distributes in the extracellular fluid and is excreted unchanged by glomerular filtration.
SCANLUX-300 (gadoxetate disodium) is a hepatobiliary MRI contrast agent that shortens T1 relaxation time, enhancing signal intensity in tissues. It is taken up by hepatocytes via OATP1B1/1B3 transporters and excreted into bile via MRP2, allowing both dynamic and hepatobiliary phase imaging.
Intravenous: 50-300 mL of a 30% solution (150-900 mg iodine/kg) as a single dose for contrast enhancement. Dosing depends on procedure and patient weight.
30 mg/m² IV over 1 hour every 4 weeks.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is 3.5 hours (range 2.8–4.5 h); may be prolonged in hepatic impairment (up to 7 h).
Renal (90-100% unchanged via glomerular filtration within 24 hours); minimal biliary/fecal (<1%)
Renal excretion of unchanged drug accounts for approximately 30% of the administered dose; fecal/biliary elimination accounts for about 60% (via hepatobiliary secretion into feces); minimal excretion via other routes.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent